Gastrointestinal Stent Market :Emerging Trends and Global Future Forecast

The increasing preference for minimally invasive surgeries and rising prevalence of GI cancers and other digestive diseases are the major factors driving the growth of the gastrointestinal stent market. The base year considered for the study is 2016, while, the forecast period is 2017 to 2022.

The global Gastrointestinal Stent Market is projected to reach USD 452.6 Million by 2022 from USD 353.4 Million in 2017, at a CAGR of 5.1% during the forecast period.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167758126

On the basis of product, the biliary stent segment accounted for the largest share of the global gastrointestinal stent market. This can be attributed to the high prevalence of pancreatic cancer and biliary diseases as well as growth in the number of surgical procedures for the treatment of these diseases.

On the basis of disease type, the biliary diseases segment accounted for the largest share of the gastrointestinal stent market. The large share of this segment is attributed to the high prevalence of gastrointestinal diseases in the elderly population.

Based on end user, the ambulatory surgery centers segment is expected to register the highest CAGR during the forecast period. Scheduling delays for operation, slow operating room turnover times, and the need for increasing the number of operating rooms in hospitals are the major factors supporting the growth of ASCs.

North America accounted for the largest share of the gastrointestinal stent market in 2016, followed by Europe and Asia Pacific. The developed healthcare system, rising geriatric population, and high prevalence of gastrointestinal cancers are the major factors responsible for the large share of North America in the gastrointestinal stent market.

Read more :- 

https://www.marketsandmarkets.com/PressReleases/gastrointestinal-gi-stent.asp

The prominent players in the global gastrointestinal stent market are Boston Scientific (US), Cook Group (US), C.R. Bard (US), ELLA-CS (Czech Republic), Becton, Dickinson and Company (US), Merit Medical Systems (US), CONMED (US), Cantel Medical (US), Olympus (Japan), Taewoong Medical (South Korea), Micro-Tech (Nanjing) (China), Endo-Flex (Germany), and M.I. Tech (South Korea).

Surgical Retractor Market - Forecasts to 2023

The major factors driving the growth of the surgical retractors market are increasing number of surgical procedures; market availability of specialized and application specific retraction products; continuous expansion of geriatric population; and rising demand for plastic and reconstructive surgeries.

The report "Surgical Retractor Market  is projected to reach USD 2.5 billion by 2023 from USD 1.8 billion in 2018, at a CAGR of 7.2%.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121697708

Based on product type, the surgical retractors market is segmented into hand-held retractors, self-retaining retractors, table-mounted retractors, wire retractors, and accessories. The hand-held retractors segment is expected to account for the largest share of the surgical retractors market in 2018. The availability of a wide range of affordable handheld retractors coupled with significant preference of healthcare providers for these products across the world and large number of surgical procedures (especially abdominal and cardiothoracic procedures) conducted across major healthcare markets is the major factor driving the growth of this market segment.

Based on applications, the surgical retractors market is segmented into abdominal applications; cardiothoracic applications; orthopedic applications; obstetric and gynecological applications; general surgical applications; head, neck, and spinal applications; aesthetic surgical applications, and other applications. The surgical retractors market for head, neck, and spinal application is expected to witness high growth rate in the during forecast period. The growing usage of application specific specialized surgical retractors in spinal surgeries and growth in number of patients with spinal disorders are the major factor driving the growth of this market segment.

Based on end user, the surgical retractors market is segmented into hospitals, clinics, and surgical centers; ambulatory care centers; and maternity and fertility centers. The hospitals, clinics, and surgical center end user segment is expected to account for the largest share during the forecast period. The growing number of surgical procedures across the globe and growth in the number of hospitals, clinics and surgeons providing surgical treatments are the key factors driving the growth of this segment.

The surgical retractors market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The North America region is expected to account for the largest share of the global surgical retractors market in 2018, and this trend is expected to continue during the forecast period. Dominant position of North America is mainly attributed to the high number of surgical procedures in the region, the presence of a well-established healthcare system, and on-going investments by hospitals to upgrade operating rooms (including surgical instruments).

Read more :- 

https://www.marketsandmarkets.com/PressReleases/surgical-retractor.asp

As of 2017, major players operating in the global surgical retractors market are JOHNSON & JOHNSON (US), MEDTRONIC PLC (US), BECTON, DICKINSON AND COMPANY (US), STRYKER CORPORATION (US), Terumo Corporation (Japan), HENRY SCHEIN, INC. (US), B. Braun Melsungen AG (Germany), TELEFLEX INCORPORATED (US), INTEGRA LIFESCIENCES HOLDINGS CORPORATION (US), THE COOPER COMPANIES, INC. (US), GLOBUS MEDICAL, INC. (US), RTI SURGICAL, INC. (US), Arthrex, Inc. (US), Invuity, Inc. (US), and Medline Industries, Inc. (US), among others.

Colposcopy Market - Global Forecast to 2023

The heavy burden of cervical cancer, rapidly growing geriatric population, and technological advancements in colposcopy are the key factors driving the growth of this market.

The Colposcopy Market is expected to reach USD 740.1 Million by 2023 from USD 532.6 Million in 2018, at a CAGR of 6.8%.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210884594            

The colposcopy market is segmented on the basis of instrument type into optical colposcopes and digital colposcopes. In 2018, the optical colposcope segment is expected to account for the largest share of the colposcopy market. The large share of this segment can be attributed to advantages such as easy installation and low cost of these instruments.

On the basis of instrument portability, the market is segmented into portable, fixed, and handheld colposcopes. The portable colposcopes segment is expected to account for the largest share of the market in 2018 and it is also expected to grow at the highest CAGR during the forecast period. 

The growth of this segment can be attributed to the advantages portable colposcopes offer, which include ease of installation and movement within medical settings, better result reproducibility, and the ability to produce high-definition images, and stable cervix examinations.

Based on region, the colposcopy market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the colposcopy market in 2018 and this trend is likely to continue during the forecast period. 

The large share of this segment can primarily be attributed to the high burden of cervical cancer, availability of technologically advanced screening tools, the presence of major players in this region, and the presence of quality healthcare infrastructure.

Read more :- https://www.marketsandmarkets.com/PressReleases/colposcopy.asp

Key players in the Colposcopy market include DySIS (US), CooperSurgical (US), Atmos (Germany), Olympus (Japan), Karl Kaps (Germany), McKesson (US), Danaher (US), and Carl Zeiss (Germany).

Blood Screening Market :Emerging Trends and Global Future Forecast

The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the key factors driving the growth of this market.

The Blood Screening Market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%. 

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

Based on product & service, the blood screening market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment accounted for the largest share of the blood screening market in 2018. The large share of this segment can be attributed to the high consumption and repeated use of reagents & kits in blood screening procedures. Also, the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs are driving the growth of the blood screening reagents & kits market.

Based on end users, the blood screening market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, an increasing number of donations worldwide, and growth in government funding to charitable trusts.

Based on region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. 

Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the blood screening market in North America.

Read more :- 

https://www.marketsandmarkets.com/PressReleases/blood-screening.asp

The prominent players operating in the blood screening market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

Nuclear Imaging Equipment Market :Emerging Trends and Global Future Forecast

Factors driving the global market include introduction of new and advanced products, investment for the modernization of diagnostic imaging centers, development of new radiotracers, and increasing incidence and prevalence of cancer & cardiovascular diseases. However, factors such as shutdown of National Research Universal (NRU) reactor, high cost of nuclear imaging equipment, and shorter half-life of radiopharmaceuticals are hindering the growth of the market.       

This report studies the global Nuclear Imaging Equipment Market for the forecast period of 2016 to 2021. This market is expected to reach USD 2.85 Billion by 2021 from USD 2.25 Billion in 2016, growing at a CAGR of 4.8%.

The global nuclear imaging equipment market is segmented on the basis of product, application, end user, and region.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=98

Based on product, the nuclear imaging equipment market is categorized into SPECT systems, hybrid PET systems, and planar scintigraphy. In 2016, the SPECT systems segment is expected to account for the largest share of the nuclear imaging equipment market. The SPECT systems are further segmented into hybrid SPECT and standalone SPECT systems. In 2016, the hybrid SPECT segment is expected to account for the largest share of the SPECT nuclear imaging equipment market. Advantages such as better imaging ability, high resolution, and the ability to show molecular processes in vivo render hybrid SPECT systems superior than standalone systems.

Based on application, the nuclear imaging equipment market is segmented into oncology, cardiology, neurology, and other applications (orthopedics, urology, thyroid-related disorders, and gastroenterology). In 2016, the oncology application segment is expected to account for the largest share of the nuclear imaging equipment applications market. The rising incidence and prevalence of cancer across the globe, initiatives taken by public and private organizations to curb the same, and development of advanced systems and radiotracers for oncology are the key factors contributing to the large share of the oncology segment.

Based on end user, the nuclear imaging market is segmented into hospitals, imaging centers, academic & research centers, and other end users (pharmaceutical & biotechnology companies and CROs). In 2016, the hospitals segment is expected to account for the largest share of the market. The rise in the use of advanced imaging solutions and hybrid imaging systems in hospitals and enhanced care quality is driving the growth of this segment.

Based on region, the nuclear imaging equipment market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The RoW region comprises Latin America, the Middle East and Africa. In 2016, North America is projected to account for the largest share of the nuclear imaging equipment market, followed by Asia-Pacific and Europe. 

Read more :- 

https://www.marketsandmarkets.com/PressReleases/nuclear-imaging-equipment.asp

The major players in the global nuclear imaging equipment market are Siemens Healthineers (Germany), Philips Healthcare (Netherlands), and GE Healthcare (U.S.).These companies are dominant in the nuclear imaging market mainly due to their well-established presence in the field of medical imaging, presence in over 50 countries, high R&D investments, and strong sales and distribution force.

Ophthalmology PACS (Picture Archiving and Communication System) Market worth $160.2 million by 2023

Rapid growth in the geriatric population, rising prevalence of eye diseases, limited number of ophthalmologists, government initiatives to encourage the adoption of EHR/EMR, and the increasing adoption of teleophthalmology are the factors driving the growth of the ophthalmology PACS market.

The global ophthalmology PACS market is projected to reach USD 160.2 million by 2023 from an estimated USD 106.6 million in 2018, at a CAGR of 8.5% during the forecast period. 

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=130879968

Based on type, the ophthalmology PACS market is segmented into standalone and integrated PACS. Among these, the integrated PACS segment is expected to command the largest share of the ophthalmology PACS market in 2018. The advantages associated with the use of integrated PACS, such as ease of deployment and use, easy interoperability, data security, portability, and cost-effectiveness are driving the growth of this segment.

Based on delivery model, the ophthalmology PACS market is segmented into on-premise and web/cloud-based models. The web/cloud-based PACS segment is expected to grow at the highest CAGR during the forecast period. The high growth rate can be attributed to the fact that, these models do not require any significant setup charges. Maintenance and support service charges are also included in subscription fees, which make these delivery models more affordable for customers.

Based on end user, the ophthalmology PACS market is segmented into hospitals, specialty clinics & ambulatory surgery centers, and other end users. In 2018, the specialty clinics & ambulatory surgical centers segment is expected to command the largest share of the ophthalmology PACS market. The growing patient pool for the diagnosis and treatment of cataracts in specialty clinics & ASCs due to cost-effective treatments is expected to propel the growth of the ophthalmology PACS market in this end-user segment.

In 2018, North America is expected to command the largest share of the market. With the growing aging population and increasing incidence of age-related eye diseases, the demand for technologies such as PACS is increasing in the North American region. Additionally, government initiatives towards digitization and increasing adoption of EHR/EMR and data storage & exchange solutions are the additional factors driving the adoption of ophthalmology PACS in this region.

Read more :- 

https://www.marketsandmarkets.com/PressReleases/ophthalmology-pacs.asp

The ophthalmology PACS market is marked by the presence of several big and small players. Prominent players in this market include Carl Zeiss Meditec AG (Germany), Topcon Corporation (Japan), Heidelberg Engineering (Germany), Sonomed Escalon (US), Visbion (UK), EyePACS (US), and IBM Corporation (Merge Healthcare) (US).

Pharmaceutical Membrane Filtration Market : Emerging Trends and Global Future Forecast

The growth of this market is primarily driven by the growth of the pharmaceutical and biopharmaceutical industry, increasing demand for single-use technologies, and the advancements in nanofiltration techniques.

The global Pharmaceutical Membrane Filtration Market is valued at an estimated USD 5.1 billion in 2019 and is projected to reach USD 8.6 billion by 2024, growing at a CAGR of 11.0% during the forecast period.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255408031

On the basis of product, the pharmaceutical membrane filtration market is segmented into filters, systems, and accessories. Filters formed the largest product segment in this market owing to the high and growing use of different types of membrane filters for various filtration applications in the biopharmaceutical manufacturing industry.

On the basis of application, the pharmaceutical membrane filtration market is segmented into final product processing, raw material filtration, cell separation, water purification, and air purification. Final product processing was the largest application segment in the pharmaceutical membrane filtration market in 2018. The increasing production of generics, rapid growth in the biopharmaceutical industry, and the increasing adoption of membrane filters in protein purification, sterile filtration, and viral clearance processes are the major factors driving the growth of this application segment.

The global pharmaceutical membrane filtration market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America was the largest market for pharmaceutical membrane filtration, followed by Europe. The large share of North America can be attributed to several factors, such as the presence of key biopharmaceutical manufacturing facilities in the region and the significant spending on research and development activities in the US.

Read more :- 

https://www.marketsandmarkets.com/PressReleases/pharmaceutical-membrane-filtration.asp

The major companies operating in the pharmaceutical membrane filtration market include Merck Millipore (Germany), Danaher (US) and Sartorius Stedim Biotech (France).

Needles Market - Global Forecast to 2022

Key factors such growing geriatric population, increasing number of hospitals in emerging markets, and high prevalence of chronic diseases are the major factors driving the growth of the needles market across the globe.

The report studies the global Needles Market over the forecast period of 2017 to 2022. The market is expected to reach USD 8.47 Billion by 2022, at CAGR of 7.8% during the forecast period. 

On the basis of type, the global needles market is segmented into two broad categories, namely, conventional needles and safety needles. The conventional needles market is estimated to command the larger share of the global needles market in 2017. The growing demand for biosimilar products, the increasing incidence of chronic disease, and the expanding injectables market are the key factors contributing to the growth of this market segment.

Download PDF Brochure:-

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223979930

Based on product, the market is segmented into suture needles, blood collection needles, ophthalmic needles, dental needles, insufflation needles, pen needles, and other needles. While the pen needles segment is expected to hold the largest share of the in 2017, it is the blood collection needles segment that is expected to grow at a significant CAGR from 2017 to 2022. Factors like the increasing number of blood donations and technological advancements in blood collection sets are driving the growth of the blood collection needles market.

The needles market is segmented into hypodermic, intravenous, intramuscular, and intraperitoneal needles on the basis of delivery mode. The hypodermic needles segment is expected to account for the largest share of the needles market in 2017. These needles are used for injecting the drug into the subcutaneous layer; this enables the quick absorption of active compounds into the bloodstream, which is a key factor contributing to the market growth of this segment.

As of 2016, North America held the largest share of the global needles market, followed by Europe. Its dominant share is attributed to the rising incidence of chronic diseases, initiatives by different organizations for the reduction in blood borne infections, and increasing prevalence of cardiovascular diseases.

Read more :-

https://www.marketsandmarkets.com/PressReleases/needles.asp

The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.).

Emerging Trends and Global Future forecast of Cholesterol Screening Testing Services Market

Factors such as increasing incidence of cardiovascular diseases and obesity, physician preference of laboratory testing rather self-testing, growing awareness and adoption of preventive healthcare, government initiatives to improve the quality of testing, and rapid growth in the geriatric population are propelling the growth of this market. Moreover, emerging economies offer significant growth opportunities for players operating in the cholesterol testing services market. On the other hand, rapidly growing home/self-testing and emergence of noninvasive cholesterol testing methods are the major factors that may limit growth of the market to a certain extent.

The global Cholesterol Screening Testing Services Market is expected to reach USD 17.57 Billion by 2021 from an estimated value of USD 11.96 Billion in 2016, growing at a CAGR of 8% during the forecast period.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180941049

The cholesterol testing services market is segmented on the basis of type of customer and region. Based on type of customer, the market is segmented into physicians/providers and hospitals; employers, health plans, and Managed Care Organizations (MCOs); government agencies, Accountable Care Organizations (ACOs), and Integrated Delivery Networks (IDNs); and patients. 

The patient-driven cholesterol testing segment is expected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness and adoption of preventive healthcare, availability of lab test services for patients without any physician intervention thus reducing the waiting time to get appointment from physicians, and online access to reports and readings through smartphones.

Based on region, the cholesterol testing services market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2016, North America is expected to dominate the market, followed by Europe. However, the cholesterol testing services market in the Asian region is expected to witness the highest CAGR during the forecast period mainly due to large population in the region, increased prevalence of cardiovascular diseases, increasing awareness in masses for preventive healthcare, and large number of testing facilities available in the Asian region.

Read more :-

https://www.marketsandmarkets.com/PressReleases/cholesterol-testing-services.asp

Prominent players in the market include Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific (Luxembourg), Spectra Laboratories Inc. (U.S.), Unilabs (Switzerland), SYNLAB International GmbH (Germany), Bio-Reference Laboratories Inc. (U.S.), Clinical Reference Laboratory, Inc. (CRL) (U.S.), ACM Medical Laboratory (U.S.), and Adicon Clinical Laboratory (China).

Covid 19 Impact on the Respiratory Diagnostics Market

The report provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.          

The global Respiratory Diagnostics Market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021.

Major factors driving the market growth are increasing prevalence of respiratory diseases, growing geriatric population, and technological advancements in respiratory diagnostic systems. On the other hand, rising healthcare costs and reimbursement concerns are the major factors restraining the growth of the respiratory diagnostics market. High potential emerging markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore offer significant growth opportunities for the key players in the respiratory diagnostics market.

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163390459

The global respiratory diagnostics market is segmented on the basis of product and service, test type, disease, end user, and region. On the basis of product and service, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and software and services. The instruments and devices segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The continuous requirement of diagnostic instruments and devices in laboratories, point-of-care, and home care is a major factor driving the uptake of instruments and devices.

On the basis of test type, the respiratory diagnostics market is broadly classified into mechanical tests, imaging tests, traditional diagnostic tests, and molecular diagnostic tests. In 2016, the traditional diagnostic tests segment is expected to account for the largest share of the respiratory diagnostics market. The large share of this segment is primarily attributed to the quick turnaround time of these tests.

On the basis of disease, the respiratory diagnostics market is segmented into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. The tuberculosis segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The large share of this segment is primarily attributed to the increase in tobacco smoking and growing air pollution levels.

On the basis of end user, the respiratory diagnostics market is categorized into hospital/clinical laboratories, reference laboratories, physician offices, and other end users (including blood banks, point-of-care testing, patient self-testing, home health agencies, nursing homes, and local public health laboratories). 

North America is expected to account for the largest share of the global respiratory diagnostics market in 2016, followed by Europe. The growth of the respiratory diagnostics market in North America is majorly driven by the rising prevalence of respiratory diseases and growing geriatric population in the region. 

Read more :-

https://www.marketsandmarkets.com/PressReleases/respiratory-diagnostics.asp

The respiratory diagnostics market is dominated by established players such as Philips Healthcare (Netherlands), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Alere, Inc. (U.S.).

Stem Cell Therapy Market - Global Forecasts to 2022

Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.

The report studies the "Stem Cell Therapy Market during the forecast period of 2016 to 2022. The market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period. 

On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period. 

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

On the basis of therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. 

On the basis of cell source, the global stem cell therapy market is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Furthermore, the bone marrow derived MSCs segment is expected to grow at highest CAGR of 12.1% during the forecast period.

North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%. 

Read more :- https://www.marketsandmarkets.com/PressReleases/stem-cells-market.asp

As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market.

US Outpatient Surgical Procedures Market US Forecast to 2023

The growing number of outpatient surgeries is expected to increase the adoption of capnography monitoring devices in outpatient surgical departments in the US.

The number of US Outpatient Surgical Procedures Market in the US is expected to grow from ~129 million procedures in 2018 to ~144 million procedures by 2023, at a CAGR of 2.1% during the forecast period. 

Download PDF Brochure :- 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94756744

By type, the dental surgeries segment accounted for the largest share of the US outpatient surgical procedures market in 2018. The large share of this market segment can be attributed to the large number of dental surgeries performed in physicians’ offices in the US, which require minimal sedation.

Other surgeries performed in outpatient departments include surgeries of the nervous system (laminectomy and excision of the intervertebral disc and decompression of the peripheral nerve), endocrine system (partial or complete thyroidectomy), and integumentary system (mastectomy and lumpectomy). 

Read more : https://www.marketsandmarkets.com/PressReleases/us-outpatient-surgical-procedures.asp

Growth in this market segment can largely be attributed to the increasing prevalence of disorders of the intervertebral disc, peripheral nerves, and glands as well as growth in the burden of breast cancer.

Multimodal Imaging Market - Global Forecast to 2024

Growing applications of multimodal imaging systems, technological advancements in diagnostic imaging modalities, availability of funding for research, favorable reimbursement scenario, growing insurance coverage, and increasing R&D into radiotracers are some of the key factors driving the multimodal imaging market.

The Multimodal Imaging Market is projected to reach USD 2.9 billion by 2024 from USD 2.3 billion in 2019, at a CAGR of 4.4%,

Based on technology, the multimodal imaging market is broadly segmented into PET/CT systems, PET/MR systems, SPECT/CT systems, OCT/Fundus Imaging systems, and other multimodal imaging systems (tri-modality systems such as SPECT/CT/PET, PET/CT + MR, and IVUS + NIRS systems, among others).

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=3358876

The PET/CT systems segment accounted for the largest share of the multimodal imaging market in 2018. This can be attributed to the increasing demand for early and accurate cancer diagnosis, growing clinical evidence for the early detection of Alzheimer’s disease, increasing applications of PET/CT systems in cardiology, favorable reimbursement scenario, and the technological advancements in the field of PET/CT.

On the basis of application, the multimodal imaging market is segmented into brain & neurology, cardiology, oncology, ophthalmology, and other applications. The oncology segment registered the highest CAGR in 2018. This can be attributed to the expanding use of multimodal imaging systems in oncology diagnosis, increasing demand for the early & accurate diagnosis of cancer, and growing clinical evidence on the use of multimodal imaging in the diagnosis of novel cancer types.

The multimodal imaging market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the multimodal imaging market owing to factors such as the increasing availability of radiotracers, technological advancements in diagnostic imaging modalities, high incidence/prevalence of diseases such as breast cancer and colorectal cancer, large number of multimodal imaging procedures performed, growing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems.

Read more :- https://www.marketsandmarkets.com/PressReleases/multimodal-imaging.asp

The major players operating in the multimodal imaging market are GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), United Imaging Healthcare Co., Ltd. (China), Canon Medical Systems Corporation (Japan), Mediso Medical Imaging Kft (Hungary), Neusoft Medical Systems Co., Ltd. (China), Spectrum Dynamics Medical (Switzerland), Infraredx, Inc. (Japan), Topcon Corporation (Japan), Carl Zeiss AG (Germany), and Heidelberg Engineering (Germany).

Catheters Market is Projected to Reach $ 24.2 Billion by 2025

The growing target patient population and the rising focus on minimally invasive surgical procedures over conventional surgery are the major factors driving the growth of this market.

The report Catheters Market is Projected to Reach USD 24.2 Billion by 2025, at a CAGR of 8.7% from 2020 to 2025

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803

On the basis of type, the global catheters market is segmented broadly into cardiovascular, urological, intravenous, neurovascular, and specialty catheters. Cardiovascular catheters commanded the largest share of the catheters market in 2019 and are expected to grow at the highest CAGR during the forecast period. This is primarily attributed to factors such as the high incidence of CVD, the growing geriatric population, and increasing awareness regarding early diagnosis. These factors have resulted in an increase in cardiovascular surgeries, which positively impacts the cardiovascular catheters market.

Based on end user, the catheters market is segmented into hospitals, long-term care facilities, diagnostic imaging centers, and other end users. In 2019, hospitals were the largest end users of catheters. This segment is expected to grow at the highest CAGR, majorly due to the high volume of target procedures performed in hospitals. The presence of big cath labs and electrophysiology labs in hospitals and a growing patient population are other key drivers of this market. The emergence of advanced diagnostic imaging catheters, coupled with the demand for minimally invasive procedures, is accelerating the adoption of catheters in hospitals.

The catheters market has been divided into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global catheters market in 2019. This is attributed to various factors such as the large number of target procedures performed in the region, the presence of a well-established healthcare system, and investments by hospitals to upgrade & expand operating capabilities.

Read more :- https://www.marketsandmarkets.com/PressReleases/catheters.asp

The prominent players operating in this market include Medtronic (Ireland), Edwards Lifesciences Corporation (US), Teleflex Incorporated (US), Abbott (US), B. Braun Melsungen AG (Germany), Becton, Dickinson and Company (US), Boston Scientific Corporation (US), ConvaTec Group (UK), Coloplast (Denmark), Johnson & Johnson Services (US), Terumo Corporation (Japan), Hollister Incorporated (US), Stryker (US), Cook Medical (US), and Merit Medical Systems (US).

Isothermal Nucleic Acid Amplification Technology Market - Global Forecast to 2024

Factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT are the key factors driving the market growth.

The report "Isothermal Nucleic Acid Amplification Technology Market  size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period. 

Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems. Assay, kits, and reagents segment are expected to account for the largest share of the INAAT industry in 2019, owing to the factors such as the increasing number of infectious disease diagnostic tests carried out; the growing prevalence of infectious diseases; the continuous launch of newer, faster, and more reliable POC products; increasing approvals of CLIA-waived tests; accessibility to a wide range of reagents; repeated purchase of reagents; and the increasing use of reagents in therapeutics, basic research, and assay development.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839

Based on the type, the global market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies. The TMA segment is expected to account for the largest share of the global INAAT industry in 2019. The large share of this segment is attributed to the growing reliance on POC diagnosis in hospitals and blood banks.

Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications such as cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis. The infectious disease diagnosis segment is expected to dominate the market in 2019 owing to the increasing number of infectious disease diagnostic tests carried out and the rising prevalence of infectious diseases, among others.

Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users. The hospital segment is expected to account for the largest share of the INAAT market in 2019 because hospitals are equipped with fully automated INAAT instruments and offer test results quickly as compared to reference laboratories. Owing to these factors, the demand for INAAT systems and consumables in hospitals is larger than the other end-user segments.

In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe. 

Read more :- https://www.marketsandmarkets.com/PressReleases/inaat-market.asp

The major companies in the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US).

Electronic Drug Delivery Systems Market - Global Forecast to 2024

Factors such as the growing prevalence of target diseases, the favorable reimbursement scenario in major markets, and advancements in technologies & designs of electronic drug delivery systems are driving the growth of the electronic drug delivery systems market during the forecast period. However, emerging economies such as China, India, Russia, and Brazil offer significant growth opportunities for players in the electronic drug delivery market. This can primarily be attributed to the diversified healthcare markets in this region, growing incidence of chronic disorders, and increasing R&D initiatives to develop innovative medical technologies.

The report "Electronic Drug Delivery Systems Market   is projected to grow at a CAGR of 8.7% during the forecast period to reach USD 11.9 billion by 2024 from USD 7.8 billion in 2019.

The electronic wearable infusion pumps segment accounted for the largest share of the electronic drug delivery systems market in 2018. This is primarily due to the rising prevalence of diabetes and the increasing availability of commercial infusion pumps for diabetes treatment. However, the high cost of electronic drug delivery devices, high acceptance of conventional devices, and lack of reimbursement for electronic drug delivery devices in developing countries could restrain the growth of this segment.

Request for Sample Report: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=165758442

The diabetes segment accounted for the largest share in 2018. This is primarily due to the high prevalence of diabetes across the globe and the greater availability of electronic drug delivery devices, such as insulin pumps and injection pens, for diabetes in comparison to other therapeutic areas. For instance, according to the International Diabetes Federation, in 2017, almost 425 million people were suffering from diabetes worldwide; this is expected to increase to 629 million by 2045.

In 2018, North America dominated the electronic drug delivery systems market, followed by Europe. High burden of target diseases, favorable reimbursement scenario, and the presence of major market players in this region are the factors propelling the growth of the market. For instance, in April 2018, AstraZeneca (UK) received OTC clearance for its SmartTouch for Symbicort (an electronic inhaler) and launched this product in the US market. Similarly, in December 2017, Companion Medical (US), launched InPen (an electronic injection pen) in the US.

Read More :- https://www.marketsandmarkets.com/PressReleases/electronic-drug-delivery-system.asp

The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).

Healthcare CRM Market by Component, Functionality, Delivery & End user 2023

The research report "Healthcare CRM Market by Component (Software, Service), Delivery (On premise, Cloud, Public, Private, Hybrid), End user (Hospital, ASC, Payers, Life Science), Functionality (CSS, Marketing, Sales, Digital Marketing, AI, Analytics) - Global Forecast to 2023", published by MarketsandMarkets™, the Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period.

Further more information in details about Healthcare CRM Market Best Chance to increase growth in revenue of your company.

Healthcare providers are expected to dominate the healthcare CRM end-user market in 2018 

Based on end user, the Healthcare CRM Market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment.

Browse in-depth TOC on “Healthcare CRM Market”

62 – Tables  

34 – Figures  

121 – Pages  

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/healthcare-crm-market-88873203.html

Healthcare CRM services to grow at the highest CAGR during 2018-2023 

On the basis of component, the Healthcare CRM Market is segmented into software and services. The services segment is expected to dominate the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the Healthcare CRM Market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment.

Request for Free Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203

North America to dominate the market, followed by Europe 

Geographically, the global Healthcare CRM Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the Healthcare CRM Market. Some of the major factors driving the growth of this market include government initiatives and regulations to encourage the adoption of healthcare IT, growing pressure on healthcare organizations to focus on patient engagement for patient retention, growing EHR adoption, growing focus of CRM providers on developing and commercializing AI and analytics-powered advanced CRM solutions, and the increasing number of ACOs. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. Factors such as the improving quality of healthcare, improvements in healthcare systems, the growing medical tourism market in Asian countries, and increasing government initiatives are the key factors driving the growth of this market.

The key players in the Healthcare CRM Market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US).

x

Hematology Analyzers and Reagents Market statistics and research analysis released in latest report

The report "Hematology Analyzers and Reagents Market by Products & Services (Hematology Analyzers (5 Parts, 6 Parts, 3 Part, PoC, Semi-Automated), Hemostasis, Immunohematology), Price Range (High, Low), End User (Government labs) - Global Forecast to 2023"


The increasing incidence of blood disorders and the growth in blood donation are the major factors driving the growth of the global hematology products market. Furthermore, factors such as technological advancements in hematology analyzers and reagents and integration of flow cytometry techniques with hematology analyzers are expected to support the growth of this market during the forecast period.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153222146  

The hematology products and services segment is expected to register the highest growth rate during the forecast period
On the basis of products & services, the hematology analyzers and reagents market is classified into hematology, hemostasis, and immunohematology products and services. The hematology products and services segment is projected to grow at the highest growth rate during the forecast period. Factors such as the increasing adoption of POC testing hematology analyzers in emerging economies, launch of technologically advanced hematology products coupled with the increasing preference towards automation, the growing trend of the ‘reagent rental’ business model, and the rising availability of a wide range of services from major hematology providers, are driving the growth of this segment.

Based on end user, the commercial service provider segment accounted for the largest share of the products and services market in 2017
By end user, the hematology products and services market is segmented into hospital laboratories, commercial service providers, government reference laboratories, and research & academic institutes. In 2017, the commercial service providers segment accounted for the largest share of the market due to the increasing awareness for hematology testing, shift from manual testing to automated testing, and competitive benefits offered by these providers as compared to hospitals (such as affordable service costs, efficient turnaround time, and efficient management for sample collection).

Read more: - https://www.marketsandmarkets.com/PressReleases/hematology-analyzers-reagents.asp

North America is expected to dominate the hematology products and services market in 2018
North America is estimated to account for the largest share of the market in 2018. This can be attributed to the rising incidence of patients suffering from blood disorders, growing prevalence of target diseases, and the rising demand for blood transfusions increasing the demand for hematology testing in the region.

The major players of the global hematology analyzers and reagents market are Sysmex (Japan), Danaher (US), Nihon Kohden (Japan), Siemens (Germany), Abbott Laboratories (US), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (US), EKF Diagnostics (UK), Mindray (China), Ortho Clinical Diagnostics (US), and Roche (Switzerland).